Ipsen’s Group Strategy

Focus. Together. For patients & society. Ipsen’s new Group strategy explained

David Loew, CEO IpsenFive months ago, I joined Ipsen as CEO. I was excited to join a company with 90 years of patient service and consistent growth, and a clear mission, to prolong and improve patients’ lives and health outcomes.

Today, I have the pleasure of kicking off a new chapter in this long history of success. Following a thorough review of what makes us thrive and where we can improve, working closely together with the Executive Leadership Team and many more colleagues across the globe, we are presenting a new Group strategy for Ipsen.

In the coming years, we will build on our strong foundation of engaged employees, agile development capabilities and global commercial footprint to drive positive impact for patients, our people and our business. Our new Group strategy positions Ipsen for long-term success and can be summed up quite simply: Focus. Together. For patients & society.

Focus: A clear sense of prioritization will drive our activities. We will reinforce our commitment to Oncology, Rare Disease and Neuroscience – areas where we have proven experience and global capabilities along with a strong network of partners. We will focus on maximizing our existing brands and strengthen and accelerate our external innovation efforts in clearly-defined segments, leveraging €3Bn in firepower over the next four years to replenish our innovative pipeline.

Together: Our employees are the hearts, brains and architects of our success. Our experienced, global team will work together to boost a culture of collaboration, patient-centricity and innovation, and we will hone our operational excellence to continue to be an employer of choice for highly engaged talent. Through prioritization and collaboration, we will drive efficiencies to support investment in our pipeline.

For patients & society: We will deliver innovative treatments that make a real difference in patients’ daily lives and partner with the entire healthcare ecosystem to ensure they have access to them. By concentrating on the right priorities, we will create sustainable, long-term growth and positive impact for all stakeholders and most importantly for patients and society.

We’ve defined four strategic priorities to achieve these ambitious goals: bring the full potential of our innovative medicines to patients; build a high-value sustainable pipeline; deliver efficiencies to enable targeted investment & growth; boost culture of collaboration and excellence.

With this new strategy concentrating on the right priorities, I am confident we will realize our vision of being a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in oncology, rare disease and neuroscience.

The next chapter in Ipsen’s storied history begins today – and I look forward to making it a reality in collaboration with our 5,700+ Ipsen colleagues and numerous partners across the world.

Group strategy

Bring the full potential of our innovative medicines to patients

Build a high-value sustainable pipeline

Deliver efficiencies to enable targeted & growth

Boost culture of collaboration & excellence

4 strategic priorities


To help commemorate #FOPAwarenessDay, @IFOPA recently created “Shoe-In” for the World’s Rarest Dictionary. They shared that striking up a conversation with strangers can be difficult when you have a #RareDisease, and conversation starters, like cool shoes, can help break the ice.

No one knows when #fibrodysplasiaossificansprogressiva (FOP) will strike: it can be silent for some time, before flaring up without warning. We’re working with @IFOPA to spread the word about this ultra- #RareDisease ahead of #FOPAwarenessDay.

#Fibrodysplasiaossificansprogressiva (FOP) is an ultra- #RareDisease that causes bone to form outside the skeleton in places such as muscles, tendons and ligaments. Learn more on our new website ahead of #FOPAwarenessDay.

Fibrodysplasia ossificans progressiva (FOP) is difficult to identify: 52% of people with the condition receive an incorrect diagnosis at first. The journey from the initial symptoms to a correct diagnosis takes an average of 1.5 years for those diagnosed since 2016. #RareDisease

We have over 25 years of experience as a global leader in the development and commercialization of neurotoxins. This drives us to provide innovative therapies for those living with neurological disorders, such as spasticity and cervical dystonia. https://t.co/Obj8HDfHf4 IpsenGroup photo

This year’s #FOPAwarenessDay on April 23 marks the 15th anniversary of the discovery of the fibrodysplasia ossificans progressiva (FOP) mutation in the gene, ACVR1. We are proud to join those living with FOP and @IFOPA in commemorating this milestone. #RareDisease
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021